Pharma's latest movers include former senior employees of AstraZeneca, Roche and Novartis.
Insilico Medicine has made cancer genomics expert Qingsong Zhu its Chief Operating Officer (COO).
The Baltimore company specialises in applying genomics to age-related diseases. Its drug discovery tool OncoFinder predicts drug efficacy through an algorithm which analyses proprietary gene expression.
Zhu has broad experience in genomics research, with a focus on bioinformatics and the use of microarray and next generation sequencing (NGS) in cancer research and drug target identification and evaluation using in vitro and in vivo models. His recent work at Insilico Medicine, where he is responsible for operations and drug discovery research, has been on improving early diagnosis and personalised cancer treatment.
Copyright - Unless otherwise stated all contents of this web site are © 2016 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Eli Lilly is conducting several experiments on the International Space Station (ISS) US National Laboratory over the...
The world’s largest modular cGMP biopharmaceutical manufacturing facility came online this week in Wuhan, China.
Valeant, Rentschler, Celgene, MannKind, and Syngene are among those welcoming new leaders for 2016. Oh, and Turing...